Rat CRP ELISA Kit (DEIA2018)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma, cell culture supernatants
Species Reactivity
Rat
Intended Use
The CD Rat CRP (C Reactive Protein) ELISA kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Rat CRP in serum, plasma, cell culture supernatants.
Contents of Kit
1. CRP Microplate (Item A)
2. Wash Buffer Concentrate (20X) (Item B)
3. Standard Protein (Item C)
4. Detection Antibody CRP (Item F)
5. HRP-Streptavidin Concentrate (Item G)
6. TMB One-Step Substrate Reagent (Item H)
7. Stop Solution (Item I)
8. Assay Diluent (Item E2)
Storage
The entire kit may be stored at -20°C for up to 1 year from the date of shipment. Avoid repeated freeze-thaw cycles. The kit may be stored at 4°C for up to 6 months. For extended storage, it is recommended to store at -80°C.
Precision
Intra-Assay CV%: <10%
Inter-Assay CV%: <12%
Sensitivity
The minimum detectable dose of Rat CRP was determined to be 200 pg/ml.
Standard Curve

Citations


Have you cited DEIA2018 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Impact of clinical and psychological factors associated with depression in patients with rheumatoid arthritis: comparative study between Germany and Brazil

CLINICAL RHEUMATOLOGY

Authors: Morf, Harriet; da Rocha Castelar-Pinheiro, Geraldo; Vargas-Santos, Ana Beatriz; Baerwald, Christoph; Seifert, Olga

Objective To investigate the prevalence of depressive symptoms and its association with clinical and psychological factors in patients with rheumatoid arthritis (RA) in Germany and in Brazil. Method A convenience sample of 267 RA patients, 176 from Germany (age 62.4 +/- 12.3 years) and 91 from Brazil (age 56.3 +/- 12.6 years), was used in this cross-sectional study. The following questionnaires were used: Beck Depression Inventory (BDI), painDETECT test, Perceived Stress Questionnaire, fatigue questionnaire (FACIT), Health Assessment Questionnaire Disability Index (HAQ-DI), and the SF-36 questionnaires (Short-Form 36 Health Survey). Disease activity score (DAS 28-CRP) and visual analogue scale (VAS) for pain were also evaluated. Statistical analysis is based on comparison of means and proportions. Statistical significance for non-normal data was evaluated by non-parametrical tests. Results Depressive symptoms were more prevalent in the Brazilian sample (44% vs 22.9%, p = 0.025). Compared to German patients, the Brazilian ones also experienced more pain (current pain status on VAS: 4.67 +/- 3.4 vs 3.67 +/- 2.31 respectively, p < 0.01), were physically more limited (1.89 +/- 1.85 vs 1.01 +/- 0.75, p = 0.012), and had higher C-reactive protein levels (7.78 +/- 18.3 vs 5.82 +/- 10.45, p = 0.028). Despite receiving a more intensive treatment, German patients presented similar disease activity when compared to Brazilian patients (DAS28-CRP: Brazil 3.4 +/- 1.5 vs Germany 3.3 +/- 1.3, p = 0.307). Conclusion Depressive symptoms are frequent in RA patients from different countries and interact with psychological disorders and the experience of pain. They contribute negatively to their well-being suggesting the need for psychoeducational strategies.

Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Authors: Zhao, Meng; Lu, Jieyu; Tang, Yihu; Dai, Yawei; Zhou, Jingxin; Wu, Yanhu

Objectives COVID-19 has become a global epidemic, and effective therapies have not been discovered up to now. We conducted this study to explore the effectiveness and safety of tocilizumab recently used for treating COVID-19. Method A comprehensive search was conducted (up to September 27, 2020), and 19 eligible records were identified according to the inclusion and exclusion criteria. The data of the studies were extracted by 2 independent reviewers and were analyzed to evaluate the safety and availability of tocilizumab for treating COVID-19. Results Thirteen retrospective case-control studies (n = 2285 patients) and 6 retrospective single-armed studies (n = 208) were retrieved in this study. In the comparison of tocilizumab treatment group (TCZ) and standard treatment group (ST), significant associations with a lower risk of admission to ICU, use of ventilation, and mortality (OR, 95% CI: 0.53, 0.26 similar to 1.09; 0.66, 0.46 similar to 0.94; 0.44, 0.36 similar to 0.55) were found in the tocilizumab treatment group. What is more, patients treated with tocilizumab had better clinical improvement compared with the patients treated with ST (OR, 1.24; 95% CI, 0.96 similar to 1.62). After taking tocilizumab, the patients had lower C-reactive protein (CRP), white blood cell count (WBC), aspartate aminotransferase (AST) (WMD, 95% CI: - 99.66, - 156.24 similar to- 43.09; - 0.95, - 1.8 similar to- 0.11; - 12.58, - 18.88 similar to-6.29) but higher troponin (WMD, 7.61; 95% CI, 3.06 similar to 12.15) than before. In addition, tocilizumab did not have significant influence on patients' neutrophil count (Neut), lymphocyte count (Lymp), platelet count (Plt), alanine aminotransferase (ALT), and creatine (WMD, 95% CI: - 0.29, - 2.91 similar to 2.33; 0.42, - 0.23 similar to 1.07; 5.2, - 2.85 similar to 13.25; 22.49, - 2.73 similar to 47.7; - 44.78, - 93.37 similar to 3.81). Conclusion Tocilizumab may have potential effectiveness to treat COVID-19 according to the results of this study. However, more large-scale studies are needed for more accurate conclusions.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket